loxoprofen has been researched along with Peptic Ulcer in 5 studies
loxoprofen: RN given refers to parent cpd without isomeric designation; structure in first source
loxoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration.
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib 100 mg b." | 6.78 | Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. ( Kawai, T; Nakamura, S; Sakamoto, C; Sugioka, T; Tabira, J, 2013) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs) are an effective and common treatment for chronic pain disorders, but long-term use is associated with risk of potentially life-threatening gastrointestinal adverse events (AEs)." | 2.78 | Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. ( Kinoshita, Y; Miwa, H; Sugano, K; Takeuchi, T, 2013) |
| "Celecoxib 100 mg b." | 2.78 | Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. ( Kawai, T; Nakamura, S; Sakamoto, C; Sugioka, T; Tabira, J, 2013) |
| "Omeprazole (100 mg/kg) was given p." | 1.36 | Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats. ( Amagase, K; Kato, S; Ochi, A; Sugihara, T; Takeuchi, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sugano, K | 1 |
| Kinoshita, Y | 1 |
| Miwa, H | 1 |
| Takeuchi, T | 1 |
| Amagase, K | 2 |
| Yoshida, Y | 1 |
| Hara, D | 1 |
| Murakami, T | 1 |
| Takeuchi, K | 2 |
| Ochi, A | 1 |
| Sugihara, T | 1 |
| Kato, S | 1 |
| Sakamoto, C | 1 |
| Kawai, T | 1 |
| Nakamura, S | 1 |
| Sugioka, T | 1 |
| Tabira, J | 1 |
| Ise, Y | 1 |
| Murota, Y | 1 |
| Takayama, K | 1 |
| Narita, M | 1 |
| Suzuki, T | 1 |
| Soh, S | 1 |
| Katayama, S | 1 |
| Hirano, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use[NCT00595517] | Phase 3 | 395 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Randomized, Placebo-Controlled, Double-Blind, Phase 4 Study To Compare The Effect Of Celecoxib 100 Mg BID, Loxoprofen 60 Mg TID And Placebo On The Gastroduodenal Mucosa In Healthy Subjects[NCT00994461] | Phase 4 | 190 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00595517)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 125 |
(NCT00595517)
Timeframe: up to 12 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 127 |
(NCT00595517)
Timeframe: up to 24 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 126 |
(NCT00595517)
Timeframe: up to 4 weeks after treatment
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 130 |
The percentage of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) |
|---|---|
| Celecoxib | 1.4 |
| Loxoprofen | 27.6 |
| Placebo | 2.7 |
The percentage of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment (The number of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment divided by participants multiplied by 100.) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) |
|---|---|
| Celecoxib | 24.3 |
| Loxoprofen | 47.4 |
| Placebo | 16.2 |
The percentage of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) | |
|---|---|---|
| Gastric ulcers | Duodenal ulcers | |
| Celecoxib | 0 | 1.4 |
| Loxoprofen | 25.0 | 5.3 |
| Placebo | 2.7 | 0 |
The percentage of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment (The number of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth. (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) | ||
|---|---|---|---|
| Gastroduodenal ulcers and/or erosions | Gastric ulcers and/or erosions | Duodenal ulcers and/or erosions | |
| Celecoxib | 36.5 | 35.1 | 4.1 |
| Loxoprofen | 53.9 | 53.9 | 5.3 |
| Placebo | 24.3 | 24.3 | 0 |
Number of subjects for each number of gastroduodenal endoscopic erosions after 2 weeks treatment (An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 erosion | 1 erosion | 2 erosions | 3 erosions | 4 erosions | 5 erosions | 6 erosions | 7 erosions | 8 erosions | 9 erosions | 10 or more erosions | |
| Celecoxib | 47 | 14 | 4 | 5 | 0 | 0 | 2 | 1 | 0 | 0 | 1 |
| Loxoprofen | 41 | 13 | 3 | 9 | 4 | 3 | 1 | 1 | 1 | 0 | 0 |
| Placebo | 29 | 5 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of subjects for each number of gastroduodenal endoscopic ulcers after 2 weeks treatment (An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 ulcer | 1 ulcer | 2 ulcers | 3 ulcers | 4 ulcers | 5 ulcers | 6 ulcers | 7 ulcers | 8 ulcers | 9 ulcers | 10 or more ulcers | |
| Celecoxib | 73 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Loxoprofen | 55 | 10 | 5 | 2 | 0 | 0 | 1 | 2 | 1 | 0 | 0 |
| Placebo | 36 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of subjects for each gastroduodenal endoscopic score (according to Mucosal Grading Scale) after 2 weeks treatment (Score 0 = normal mucosa (no visible lesions); Score 1 = 1 to 10 petechiae; Score 2 = more than 10 petechiae; Score 3 = 1 to 5 erosions; Score 4 = 6 to 10 erosions; Score 5 = 11 to 25 erosions; Score 6 = more than 25 erosions; Score 7 = ulcer) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Score 0 | Score 1 | Score 2 | Score 3 | Score 4 | Score 5 | Score 6 | Score 7 | |
| Celecoxib | 38 | 8 | 1 | 22 | 4 | 0 | 0 | 1 |
| Loxoprofen | 33 | 2 | 0 | 19 | 1 | 0 | 0 | 21 |
| Placebo | 22 | 6 | 0 | 8 | 0 | 0 | 0 | 1 |
2 trials available for loxoprofen and Peptic Ulcer
| Article | Year |
|---|---|
Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Esomeprazole; Fema | 2013 |
Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Cycloo | 2013 |
3 other studies available for loxoprofen and Peptic Ulcer
| Article | Year |
|---|---|
Prophylactic effect of egualen sodium, a stable azulene derivative, on gastrointestinal damage induced by ischemia/reperfusion, double antiplatelet therapy and loxoprofen in rats.
Topics: Animals; Aspirin; Azulenes; Benzoquinones; Clopidogrel; Gastric Mucosa; Gastrointestinal Hemorrhage; | 2013 |
Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats.
Topics: 16,16-Dimethylprostaglandin E2; Acetamides; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer A | 2010 |
[The analysis of prescription frequency and the factors on adverse reactions of NSAIDs for post-operative pain in orthopedic patients].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cost Savings; Drug Prescriptions; Female; Heal | 2003 |